Roche’s PATHWAY HER2 (4B5) test helps identify patients with HER2-ultralow breast cancer, who may be eligible for targeted ...

The U.S. Food and Drug Administration has approved Datroway (datopotamab deruxtecan-dlnk) for adult patients with ...

A MUM has shared a shocking photo of a giant lump protruding from her breast, which doctors repeatedly dismissed a benign.

The researchers found that imlunestrant prolonged progression-free survival (PFS) when compared to standard care in patients with ESR1 mutations, but there was no PFS benefit observed in the overall ...

T-DM1 sustained the improvement in invasive disease-free survival over trastuzumab in HER2-positive early breast cancer.

Among patients with advanced PIK3CA-mutated, HR-positive/HER2-negative breast cancer, Itovebi-based treatment generated positive overall survival results.

The FDA clearance aids AstraZeneca and Daiichi Sankyo’s plan to position ADCs like Enhertu ahead of chemotherapy in a variety ...

Enhertu first secured approval in 2019 for patients with high levels of HER2, a protein that promotes cancer cell growth. In ...

The FDA approved trastuzumab deruxtecan for adult patients with unresectable or metastatic HER2-low or HER2-ultralow breast ...

Extensive research shows that drinking alcohol increases the risk of cancer, and U.S. public-health authorities are following the example of other countries in increasing public awareness about ...

Beloved TV host Ananda Lewis shares her story and a message to Black women about prioritizing their health in the new year.

Datopotamab deruxtecan-dlnk significantly improves progression-free survival in HR-positive, HER2-negative breast cancer compared with chemotherapy. The TROPION-Breast01 trial showed a higher ...